RFM
TEVA icon

Royal Fund Management’s Teva Pharmaceuticals TEVA Stock Holding History

Royal Fund Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-400
Closed -$3K – 524
2020
Q1 		$3K Hold
400
– – ﹤0.01% 473
2019
Q4 		$3K Hold
400
– – ﹤0.01% 527
2019
Q3 		$2K Buy
+400
New +$3.06K ﹤0.01% 532

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Fund Management's TEVA Position: Q2 2020 in Review

Royal Fund Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2020, closing a stake of 400 shares — an estimated $3K sold.

Royal Fund Management first reported a position in TEVA in Q3 2019 and held it in 3 quarters. The position peaked at $3K in Q1 2020. 455 funds tracked by Wall St. Rank hold TEVA as of Q2 2020.

  • Royal Fund Management reported no remaining Teva Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Royal Fund Management sold 400 Teva Pharmaceuticals shares in Q2 2020, an estimated $3K.
  • Royal Fund Management first reported a position in Teva Pharmaceuticals in Q3 2019 and held it in 3 quarters.
  • Royal Fund Management's Teva Pharmaceuticals position peaked at $3K in Q1 2020.
  • 455 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2020.

Based on Royal Fund Management's 13F filing for Q2 2020, filed 6 Aug 2020.